9 registrations that name spirulina as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT06936202
Effects of Spirulina Supplementation on Mental Health in Healthy Adults
No phase
Arizona State University
About 30 people
Started Apr 15, 2025
In plain words A study of spirulina in people 16 to 65, run by Arizona State University. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 65; healthy volunteers accepted. Conditions: Depression; Mental Acuity.
healthy adults
ages 18-65
no underlying chronic disease or acute conditions
no autoimmune conditions
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spirulina capsules; Placebo
Registered summary
Spirulina platensis is a form of cyanobacteria, a blue-green algae, and is a superfood most known for being rich in protein, vitamins and minerals, and healthful phytochemicals. Spirulina supports brain health through neuroprotection offered by its antioxidants, anti-inflammatory properties, and hormone regulation. The aim of this study is to supplement healthy adults from a campus community with 3g of spirulina, daily, for 8 weeks to improve mood and mental acuity in comparison to receiving a placebo.
Where, as registered
1 US site in 1 state.
RecruitingNCT07173062
Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome
No phase
Universidade do Porto
About 150 people
Started Mar 11, 2025
In plain words A study of spirulina in people 50 and older, run by Universidade do Porto. It plans to enroll about 150 people at 1 site, none in the US.
History of stroke, coronary artery disease, myocardial infarction, peripheral artery disease, chronic kidney disease (eGFR <75 ml/min at least for 3 months), albuminuria >300 mg/g, or diabetes mellitus
No antibiotics in the previous 30 days
12 more inclusion criteria and the exclusion criteria are on the listing.
The Western diet, rich in fat and sugar, contributes to cardiovascular risk and alters the body metabolism, specifically through the modulation of the microbiome. Microbiome is considered the "second genome", functioning as an endocrine-like organ. Gut microbiota-derived metabolites, namely trimethylamine- N-oxide and short-chain fatty acids have been associated with atherosclerosis, vascular and cardiac diseases. Regarding trimethylamine- N-oxide, its association with cardiovascular disease is positive and dose-dependent. The full summary is on the listing.
Where, as registered
No US site; Portugal (1).
RecruitingNCT07733362
Assessment of the Immunomodulatory Potential of Spirulina Blue Protein Capsule on Immunomodulation in Healthy Volunteers
No phase
University of Phayao
About 54 people
Starts Aug 15, 2026 (estimated)
In plain words A study of spirulina in people 25 to 60, run by University of Phayao. It plans to enroll about 54 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 60; healthy volunteers accepted. Conditions: Healthy Volunteers; Immune System.
Healthy male or female adults aged 25-60 years.
Body mass index (BMI) between 18.5 and 24.9 kg/m².
Able and willing to provide written informed consent.
Willing and able to comply with all study procedures and scheduled visits
The exclusion criteria are on the listing.
What it tests, as registered
Spirulina capsules
Registered summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and immunomodulatory effects of Spirulina Blue Protein capsules in healthy adults. Participants will be randomly assigned to receive placebo, 200 mg/day, or 1,000 mg/day of Spirulina Blue Protein capsules for 12 weeks. The study will assess changes in immune cell populations (CD4+, CD8+, and natural killer cells), circulating cytokine levels, hematological and biochemical parameters, and the occurrence of adverse events. The full summary is on the listing.
Where, as registered
No US site; Thailand (1).
RecruitingNCT07723612
The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral Mucosa
No phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
About 40 people
Started Jun 1, 2026
In plain words A study of spirulina in people 18 to 100, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 100. Conditions: Recurrent Aphthous Stomatitis; Mouth Ulcer.
Adults aged 18 years or older.
Patients with radiation-induced oral mucositis (RIOM), recurrent aphthous stomatitis (RAS), or other clinically diagnosed oral ulcers, confirmed by clinical examination.
Presence of at least one clinically active oral ulcer at the time of enrollment.
Able to understand the study procedures and provide written informed consent.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Spirulina Tablets; Placebo Tablets
Registered summary
This is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of spirulina supplementation in patients with radiation-induced oral mucositis (RIOM) receiving radiotherapy for head and neck cancer. Participants will be randomly assigned to receive either spirulina tablets or placebo in addition to standard oral care during radiotherapy. The primary objective is to determine whether spirulina reduces the severity of oral mucositis. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07263217
Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
No phase
Second Affiliated Hospital, Zhejiang University, School of Medicine
About 30 people
Started Oct 1, 2025
In plain words A study of spirulina in people 18 to 75, run by Second Affiliated Hospital, Zhejiang University, School of Medicine. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Cholangiocarcinoma.
Diagnosed with cholangiocarcinoma (bile duct cell carcinoma).
Child-Pugh Class A liver function.
Planned to receive neoadjuvant therapy with gemcitabine + oxaliplatin, combined with lenvatinib and a PD-1 inhibitor, followed by anatomical hemihepatectomy (remaining liver volume > 40%).
Age 18-75 years, male or female. Willing and able to comply with the study protocol, including oral administration of spirulina or placebo for 3 weeks before and 3 weeks after surgery.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spirulina; Maltodextrin
Registered summary
The goal of this clinical trial is to learn if spirulina can help protect the liver and promote recovery after partial hepatectomy (surgery to remove part of the liver). It will also learn about the safety of spirulina in patients undergoing liver surgery. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07537192
Inulin-Spirulina Co-intervention for Insomnia Disorder
No phase
First Affiliated Hospital of Zhejiang University
About 180 people
Starts May 1, 2026 (estimated)
In plain words A study of spirulina in people 18 to 60, run by First Affiliated Hospital of Zhejiang University. It plans to enroll about 180 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Insomnia Disorder; Sleep Initiation and Maintenance Disorders.
Aged 18 to 60 years;
Meet the ICSD-3 diagnostic criteria for chronic insomnia disorder;
Pittsburgh Sleep Quality Index (PSQI) total score > 5;
Willing to participate and provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Inulin; Spirulina; Maltodextrin
Registered summary
The goal of this clinical trial is to learn if inulin and spirulina, used alone or in combination, can improve insomnia disorder in adults aged 18 to 60 years with chronic insomnia disorder. It will also learn about the safety of these interventions. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07060872
the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period.
No phase
Shahid Sadoughi University of Medical Sciences and Health Services
About 82 people
Starts Jul 7, 2025 (estimated)
In plain words A study of spirulina in people 3 to 7, run by Shahid Sadoughi University of Medical Sciences and Health Services. It plans to enroll about 82 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 7. Conditions: Age 3 to 7 Years; Mild Autism Spectrum; no Other Illness or Disorder.
Children diagnosed with non-idiopathic autism, confirmed by a pediatric neurology subspecialist
Age range: \[3 to 7 years\]
Parental informed consent obtained
Ability to complete online anxiety questionnaires with parental assistance
The exclusion criteria are on the listing.
What it tests, as registered
Spirulina Syrup; Placebo Syrup; Risperidone
Registered summary
The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Patients are randomly assigned to two groups. The intervention group receives standard treatment (Risperidone tablets) plus Spirulina syrup, while the control group receives Risperidone plus a placebo. The full summary is on the listing.
Where, as registered
No US site; Iran (1).
Not yet recruitingNCT07718399
Spirulina Supplementation in Postmenopausal Women
No phase
Halic University
About 66 people
Starts Jul 2026 (estimated)
In plain words A study of spirulina in female participants 45 to 65, run by Halic University. It plans to enroll about 66 people at 1 site, none in the US.
Having a body mass index (BMI) between 25 and 29.9 kg/m²
Having no chronic illnesses
Being between the ages of 45 and 65
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spirulina; Placebo
Registered summary
The purpose of this study is to investigate the effects of spirulina supplementation on weight gain associated with menopause, changes in metabolic parameters, sleep quality, and markers of depression in mildly overweight postmenopausal women, and to evaluate the changes that occur in these parameters.
In plain words A study of spirulina in people 18 to 75, run by Guangzhou Institute of Respiratory Disease. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Immune Checkpoint Inhibitor-Related Pneumonitis; Drug-Related Side Effects and Adverse Reactions; Neoplasms.
Voluntary participation with full understanding of the study and signed informed consent form.
Age 18 to 75 years (inclusive) on the day of informed consent signing.
Histologically or cytologically confirmed malignancy.
Received at least one cycle of immune checkpoint inhibitor therapy.
3 more inclusion criteria and the exclusion criteria are on the listing.
This is a prospective, single-center, open-label, randomized controlled clinical trial evaluating whether the addition of a nutritional therapy regimen (Spirulina-Bifidobacterium capsules, fish oil-grape seed-blueberry soft capsules, and Ganoderma spore oil) to standard glucocorticoid therapy improves outcomes in patients with Grade 3-4 immune checkpoint inhibitor-related pneumonitis (CIP), compared with standard glucocorticoid therapy alone. The full summary is on the listing.